Диссертация (1174275), страница 27
Текст из файла (страница 27)
Hellings W.E. Composition of carotid atherosclerotic plaque is associated withcardiovascular outcome: a prognostic study/ W.E. Hellings, W. Peeters, F.L.Moll et al.// Circulation. -2010. - №121(17). – Р.1941–1950.162133. Hermus L. Imaging the vulnerable carotid artery plaque/ L. Hermus, I.F.J.Tielliu, B.M. Wallis de Vries et al.// Acta Chir Belg. – 2010. - №110. – Р.159–164.134. Hosseini A.A.
Carotid plaque hemorrhage onmagnetic resonance imagingstrongly predicts recurrent ischemia and stroke/ A.A. Hosseini, N. Kandiyil,S.T. Macsweeney et al.// Ann Neurol. – 2013. - №73. – Р.774–784.135. Iwamoto T. Evaluation of B-mode ultrasonographic images of carotid lesionsby computer analysis as compared with visual assessment/ T. Iwamoto, K.Shinozaki, A. Kiuchi et al.// J Stroke Cerebrovasc Dis. – 2003. - №12.
– Р.59–65.136. Jalbert J.J. Outcomes after carotid artery stenting in Medicare beneficiaries,2005 to 2009/ J.J. Jalbert, L.L. Nguyen, M.D. Gerhard-Herman et al.// JAMANeurol. – 2015. - №72(3). – Р.276–286.137. Jastrzebska M. Factors influencing multiplate whole blood impedance plateletaggregometry measurements, during aspirin treatment in acute ischemic stroke:A pilot study/M. Jastrzebska, K. Chelstowski, A.
Wodecka et al.// BloodCoagul Fibrinol. – 2013. - №24. – Р.830–838.138. Jørgensen L. Glycated hemoglobin level is strongly related to the prevalence ofcarotid artery plaques with high echogenicity in nondiabetic individuals: TheTromsø study/ L.
Jørgensen, T. Jenssen, O. Joakimsen et al.// Circulation. –2004. - №110. – Р.466–470.139. Katsiki N. Ezetimibe therapy for dyslipidemia: an update/ N. Katsiki, E.Theocharidou, A. Karagiannis et al.// Curr Pharm Des. – 2013. - №19(17). –Р.3107-3114.140. Kernan W.N. Guidelines for the prevention of stroke in patients with strokeand transient ischemic attack: a guideline for healthcare professionals from theAmerican Heart Association/American Stroke Association/ W.N. Kernan, B.Ovbiagele, H.R. Black et al.// Stroke J Cereb Circ. – 2014. - №45.
– Р.2160–2236.163141. Kinsella J.A. Prevalence of ex vivo high on-treatment platelet reactivity onantiplatelet therapy after transient ischemic attack or ischemic stroke on thePFA-100((R)) and VerifyNow((R))/ J.A. Kinsella, W.O. Tobin, D. Cox et al.//J Stroke Cerebrovasc Dis. – 2013. - №22.
– Р.84–92.142. Krasopoulos G. Aspirin resistance and risk of cardiovascular morbidity:systematic review and meta-analysis/ G. Krasopoulos, S.J. Brister, W.S.Beattie, M.R. Buchanan // BMJ. – 2008. - №336(7637). – Р.195–198.143. Lal B.K. Restenosis after carotid artery stenting and endarterectomy: asecondary analysis of CREST, a randomised controlled trial/ B.K. Lal, K.W.Beach, G.S. Roubin et al.// Lancet Neurol. – 2012. - №11. – Р.755-763.144. Lal B.K. Pixel distribution analysis of B-mode ultrasound scan images predictshistologic features of atherosclerotic carotid plaques/ B.K. Lal, R.W. Hobson,P.J.
Pappas et al.// J Vasc Surg. – 2002. - №35. – Р.1210–1217.145. Lattimer C.R. Recurrent carotid stenosis after carotid endarterectomy/ C.R.Lattimer, K.G. Burnand // Br J Surg. – 1997. - №84.- Р.1206-1219.146. Lown B. A Maverick’s Lonely Path in Cardiology (Essay 28). – 2012. – 324 Р.147. Macchi L. Aspirin resistance: definitions, mechanisms, prevalence, and clinicalsignificance/ L. Macchi, N. Sorel, L.
Christiaens// Curr Pharm Des. – 2006. №12(2).- Р.251–258.148. Madani A. High-risk asymptomatic carotid stenosis: ulceration on 3Dultrasound versus TCD microemboli/ A. Madani, V. Beletsky, A. Tamayo etal.// Neurology. – 2011. - №77(8). – Р.744–750.149. Mammen E.F. PFA-100 system: A new method for assessment of plateletdysfunction/ E.F.
Mammen, P.C. Comp, R. Gosselin et al.// Semin ThrombHemost. – 1998. - №24. – Р.195–202.150. Mannheim D. Carotid endarterectomy with a polyurethane patch versusprimary closure: a prospective randomized study/ D. Mannheim, B. Weller, E.Vahadim, R. Karmeli// J Vasc Surg.
– 2005. - №41. – Р.403.151. Mannu G.S. The clinical utility of Multiplate analyser measurement in plateletfunction testing following stroke and transient ischaemic attack/ G.S. Mannu,164A. Macartney, J.R. Lambert et al.// Eur J Haematol. – 2015. - №94. – Р.138–144.152. Markus H.S. Asymptomatic embolisation for prediction of stroke in theAsymptomatic Carotid Emboli Study (ACES): a prospective observationalstudy/ H.S.
Markus, A. King, M. Shipley et al.// Lancet Neurol. – 2010. №9(7). – Р.663–671.153. Marquardt L. Low risk of ipsilateral stroke in patients with asymptomaticcarotid stenosis on best medical treatment: a prospective, population-basedstudy/ L. Marquardt, O.C. Geraghty, Z. Mehta, P.M. Rothwell// Stroke. – 2010.- №41(1). – Р.11–17.154. Maruyama H. Clopidogrel resistance and the effect of combination cilostazolin patients with ischemic stroke or carotid artery stenting using the VerifyNowP2Y12 Assay/ H. Maruyama, H. Takeda, T.
Dembo et al.// Intern Med. – 2011.- №50.- Р.695–698.155. Mas J.L. EVA-3S Investigators. Long-term follow-up study of endarterectomyversus angioplasty in patients with symptomatic severe carotid stenosis trial/J.L. Mas, C. Arquizan, D. Calvet et al.// Stroke. – 2014. - №45. – Р.2750-2756.156. Mathiesen E.B. Prevalence of and risk factors associated with carotid arterystenosis: the Tromso Study/ E.B. Mathiesen, O.
Joakimsen, K.H. Bonaa//Cerebrovasc Dis Basel Switzerland. -2001. - №12. – Р.44–51.157. McCabe D.J. Measurement of the antiplatelet effects of aspirin incerebrovascular disease/ D.J. McCabe, P. Harrison, S.J. Machin et al.// Stroke.– 2004. - №35. – Р.146–147.158. McGrogan D.
Implementation of best medical therapy for cardiovascular riskfactors in vascular surgery patients treated in a tertiary referral regional unit/ D.McGrogan, D. Mark, B. Lee, M.E. O’Donnell// Int J Clin Pract. – 2014. №68(9). – Р.1100-1109.159. Meves S.H. Effectiveness of antiplatelet therapy in atherosclerotic disease:Comparing the ASA low-response prevalence in CVD, CAD and PAD/ S.H.165Meves, T. Hummel, H.G. Endres et al.// J Thromb Thromb. – 2014. - №37. –Р.190–201.160. Meves S.H. Dose-dependent effect of early antiplatelet therapy in acuteischaemic stroke/ S.H. Meves, U.
Overbeck, H.G. Endres et al.// ThrombHaemost. – 2012. - №107. – Р.69–79.161. Mozaffarian D. American Heart Association Statistics Committee and StrokeStatistics Subcommittee. Heart disease and stroke statistics–2015 update: areport from the American Heart Association/ D. Mozaffarian, E.J. Benjamin,A.S. Go et al.// Circulation.
– 2015. - №131(4). – Р.29-322.162. Mueller T. Utility of whole blood impedance aggregometry for the assessmentof clopidogrel action using the novel Multiplate analyzer – Comparison withtwo flow cytometric methods/ T. Mueller, B. Dieplinger, W. Poelz et al.//Thromb Res.
– 2007. - №121. – Р.249–258.163. Barnett H.J.M. NASCET Collaborators. Beneficial effect of carotidendarterectomy in symptomatic patients with high-grade carotid stenosis/H.J.M. Barnett, D.W. Taylor, R.B. Haynes et al.// N Engl J Med. – 1991. №325. – Р.445–507.164. Naylor A.R. Randomized study of carotid angioplasty and stenting versuscarotid endarterectomy: a stopped trial/ A.R. Naylor, A.
Bolia, R.J. Abbott etal.// J Vasc Surg. -1998. - №28(2). – Р.326–334.165. Naylor A.R. Who benefits most from intervention for asymptomatic carotidstenosis: patients or professionals?/ A.R. Naylor, P.A. Gaines, P.M. Rothwell//Eur J Vasc Endovasc Surg. – 2009. - №37(6). – Р.625–632.166. Naylor A.R. Randomized trial of vein versus Dacron patching during carotidendarterectomy: long-term results/ A.R. Naylor, P.D.
Hayes, D.A. Payne// JVasc Surg. – 2004. - №39. – Р.985-993.167. Naylor A.R. Clinical and imaging features associated with an increased risk oflate stroke in patients with asymptomatic carotid disease/ A.R. Naylor, T.V.Schroeder, H. Sillesen// Eur J Vasc Endovasc Surg. – 2014. - №48(6). – Р.633–640.166168. Naylor A.R. The brighter the light, the darker the shadow/ A.R. Naylor//Stroke. – 2015. - №46(1. – Р.9–10.169. Naylor A.R. Time to rethink management strategies in asymptomatic carotidartery disease/ A.R. Naylor // Nat Rev Cardiol. – 2012. - №9.
– Р.116–124.170. Ostergaard K. Discontinuation of antiplatelet treatment and risk of recurrentstroke and all-cause death: a cohort study/ K. Ostergaard, A. Pottegard, J.Hallas// Neuroepidemiology. -2014. - №43(1). – Р.57-64.171. Paraskevas K.I.
Optimal management of patients with symptomatic andasymptomatic carotid artery stenosis: work in progress/ K.I. Paraskevas, A.L.Abbott, F.J. Veith // Expert Rev Cardiovasc Ther. – 2014. - №12(4). – Р.437441.172. Paraskevas K.I. Statins: an essential component in the management of carotidartery disease/ K.I. Paraskevas, G. Hamilton, D.P. Mikhailidis // J Vasc Surg. –2007. - №46(2). – Р.373-386.173. Paraskevas K.I. Optimal contemporary management of symptomatic andasymptomatic carotid artery stenosis/ K.I. Paraskevas, D.P.
Mikhailidis, W.S.Moore, F.J. Veith// Vascular. -2011. - №19(3). – Р.117-120.174. Paraskevas K.I. Identifying which patients with asymptomatic carotid stenosiscould benefit from intervention/ K.I. Paraskevas, J.D. Spence, F.J.Veith, A.N.Nicolaides// Stroke. - 2014. - №45(12). – Р.3720-3724.175. Paraskevas K.I. Statins and noncardiac vascular disease/ K.I. Paraskevas, A.S.Wierzbicki, D.P. Mikhailidis// Curr Opin Cardiol. – 2012. - №27(4). – Р.392397.176. Partovi S. Contrast-enhanced ultrasound for assessing carotid atheroscleroticplaque lesions/ S. Partovi, M.
Loebe, M. Aschwanden, et al.// Am JRoentgenol. – 2012. - №198.- Р.13–19.177. Phan K. Statin treatment non-adherence and discontinuation: clinicalimplications and potential solutions/ K. Phan, Y.H. Gomez, L. Elbaz, S.S.Daskalopoulou// Curr Pharm Des. - 2014. - №20(40). – Р.6314-6324.167178.
Reifler E.J. Carotid Endarterectomy A Shared Decision Making LostOpportunity/ E.J. Reifler, P. Wescott// http://www.powershow.com/view/122b6b-MzBkY/Carotid_Endarterectomy_A_Shared_Decision_Making_Lost_Opportunity_powerpoint_ppt_presentation2009(AccessedAugust 24, 2017).179.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
